The Federal Trade Commission has begun outlining its case against Edwards Lifesciences' proposed purchase of the heart ...

AbbVie is opening submissions for an award that will provide one Canadian biotech with free access to lab space and executive ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having ...

GE HealthCare is raising the curtain on its spearhead into the field of photon-counting CT, the Photonova Spectra, with an ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

A drug safety group has delivered a positive analysis for a Sarepta Therapeutics-licensed RNA medicine, with the same study ...

Swedish biotech Sprint Bioscience is selling off an early-stage TREX1 cancer program to Gilead for $14 million upfront, plus ...

VC Versant Ventures is unveiling Dayra Therapeutics, a new biotech working on oral macrocyclic peptide drugs—a mission that ...

Abbott has launched an effort to replace some of its FreeStyle Libre 3 continuous glucose monitors—following reports of ...

Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. | Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease ...

Johnson & Johnson MedTech is expanding its stroke-focused R&D in Ireland, building on previous investments and coming on the ...

Solventum estimates that Acera will likely post about $90 million in sales for 2025. The deal is expected to be "slightly dilutive" to adjusted earnings per share in 2026 and accretive to adjusted ...